Two Sigma Securities LLC Buys New Shares in Zoetis Inc. $ZTS

Two Sigma Securities LLC purchased a new position in shares of Zoetis Inc. (NYSE:ZTS) in the second quarter, HoldingsChannel.com reports. The firm purchased 42,431 shares of the company’s stock, valued at approximately $3,049,000.

Several other hedge funds have also recently made changes to their positions in ZTS. Prosperity Bancshares Inc acquired a new stake in shares of Zoetis during the 4th quarter worth approximately $25,000. Cassaday & Co Wealth Management LLC acquired a new position in shares of Zoetis during the first quarter valued at about $28,000. Elyxium Wealth LLC acquired a new position in shares of Zoetis during the fourth quarter valued at about $32,000. Root Financial Partners LLC boosted its position in shares of Zoetis by 66.5% during the 1st quarter. Root Financial Partners LLC now owns 258 shares of the company’s stock worth $30,000 after purchasing an additional 103 shares in the last quarter. Finally, Wellington Grp LLC boosted its position in shares of Zoetis by 6,675.0% during the 1st quarter. Wellington Grp LLC now owns 271 shares of the company’s stock worth $32,000 after purchasing an additional 267 shares in the last quarter. 92.80% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages recently commented on ZTS. Citigroup decreased their target price on Zoetis from $112.00 to $96.00 and set a “buy” rating for the company in a research report on Tuesday, August 11th. UBS Group cut their price target on Zoetis from $85.00 to $80.00 and set a “neutral” rating on the stock in a report on Friday, August 7th. Stifel Nicolaus reduced their price objective on Zoetis from $85.00 to $80.00 and set a “hold” rating for the company in a research note on Thursday, August 20th. Morgan Stanley set a $85.00 price objective on Zoetis in a report on Friday, August 7th. Finally, Cantor Fitzgerald set a $94.00 target price on Zoetis in a research report on Tuesday, August 25th. Eight research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $107.43.

Zoetis Trading Up 0.1%

Shares of Zoetis stock opened at $77.45 on Monday. The company has a market capitalization of $32.00 billion, a P/E ratio of 12.76, a price-to-earnings-growth ratio of 1.80 and a beta of 0.73. The stock has a fifty day simple moving average of $75.57 and a 200 day simple moving average of $95.40. Zoetis Inc. has a 12-month low of $71.00 and a 12-month high of $156.49. The company has a current ratio of 3.08, a quick ratio of 1.84 and a debt-to-equity ratio of 2.87.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Thursday, August 6th. The company reported $1.87 earnings per share for the quarter, beating the consensus estimate of $1.85 by $0.02. The business had revenue of $2.47 billion for the quarter, compared to analysts’ expectations of $2.50 billion. Zoetis had a return on equity of 74.89% and a net margin of 27.49%.The business’s revenue was down .2% on a year-over-year basis. During the same period last year, the business earned $1.76 EPS. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. On average, sell-side analysts anticipate that Zoetis Inc. will post 6.2 earnings per share for the current fiscal year.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.